Buy the Bust - A Controlled Long on Hims & Hers After the GLP-1 Collapse
Hims & Hers (HIMS) has been hammered by an FDA crackdown and a patent suit tied to its copycat GLP-1 pill, sending the stock to 52-week lows. The sell-off appears disproportionate relative to a still-profitable telehealth core: $3.54B market cap, positive free cash flow, and a leverageable acquisition pipeline. This trade idea lays out a mid-term (…